About this Research Topic
Considering the global epidemiology of GI disorders and sepsis, biomarkers enable and improve their diagnosis, prognosis, and treatment. This research topic highlights the effectiveness and limitations of biomarkers used in GI disorders, such as gut barrier proteins and microbial fermentation byproducts, including short-chain fatty acids, calprotectin, several microRNAs (miRNAs) including miRNA-146a, fatty acid-binding protein, urinary metabolomics (tricarboxylic acid and amino acids). This research topic also covers the application of other potential noninvasive biomarkers for diagnosing and monitoring GI disorders. GI cancers are widely regarded as the most harmful and clinically severe conditions affecting the digestive system. In individuals who do not exhibit clinical signs, biomarkers can function as a valuable tool for screening to detect cancer at an early stage or identify precancerous states and, in symptomatic patients, can help distinguish between cancerous and benign conditions. Additionally, with surgical intervention in cancer patients, biomarkers can be useful to assess the efficacy of tumor eradication (remission) and the likelihood of disease relapse. This research topic addresses the latest developments in genetic biomarkers but is not limited to miRNAs and long non-coding RNAs, KRAS mutations, the role of carcinoembryonic antigen, and circulating tumor DNA (ctDNA) as molecular biomarkers for GI malignancies. This topic also explores recent advancements in sepsis biomarkers, including damage-associated molecular patterns (DAMPs), pattern recognition molecules (PRMs), non-coding RNAs, miRNAs, cytokines, cell membrane receptors, metabolites, and soluble receptors. It also discusses the therapeutic challenges posed by antimicrobial resistance and their impact on One Health.
All articles must include genomics or omics data as a central part of their methods. The Research Topic aims to focus on the latest advancements in the field, encompassing both basic research and clinical studies, and invites submissions of Original Research, Reviews, and Methods but is not confined to the following areas:
• Fecal biomarkers for diagnosing and monitoring gastrointestinal disorders
• Identification and characterization of biomarkers for colorectal cancer
• Non-invasive biomarkers for gastrointestinal illnesses
• MicroRNA (miRNA) biomarkers in GI diseases
• Sepsis Biomarkers
• Signaling pathways in sepsis and GI diseases
• Epigenetic biomarkers for GI cancer diagnosis and prognosis
• GI disease epigenetic mechanisms
• Epigenetic biomarkers for GI diseases and sepsis
Keywords: Gastrointestinal disorders, Sepsis, miRNA;, Biomarkers;, Epigenetics;, Inflammatory Bowel Disease, Antimicrobial resistance, One Health, Cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.